Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants

 

• Expanding existing COVID-19 vaccine research collaboration which began in July 2020.

• Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against two or more of the current and future COVID-19 variants (e.g., tetravalent or quadrivalent COVID-19 vaccines)

• Exclusive license for Republic of Korea and multiple Southeast Asian countries, if successful

• Manufacturing protocols to produce vaccines from C1 have been successfully transferred and reproduced at Medytox

https://finance.yahoo.com/news/dyadic-medytox-develop-vaccines-against-123000403.html